Profile data is unavailable for this security.
About the company
IXICO plc is a United Kingdom-based medical imaging advanced analytics company. The Company is engaged in delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's disease, Parkinson's disease and Alzheimer's disease. It advances medicine and human health by turning data into clinically meaningful information, providing new insights in neuroscience by supporting pharmaceutical companies across all phases of central nervous system (CNS) clinical research. Its services include the collection, analysis, management, and reporting on data generated in the course of a clinical study. Its data platforms include TrialTracker and Assessa. The TrialTracker platform provides a secure and compliant environment for the collection, analysis and interpretation of large image files and other data. Its neuroimaging biomarkers focus area includes Radiological Reads, Volumetric MRI, PET and SPECT, and Advanced MRI.
- Revenue in GBP (TTM)6.00m
- Net income in GBP-1.87m
- Incorporated1995
- Employees89.00
- LocationIXICO PLC4th Fl, Griffin Court, 15 Long LaneLONDON EC1A 9PNUnited KingdomGBR
- Phone+44 203 763 7499
- Fax+44 207 209 2473
- Websitehttps://ixico.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TheraCryf PLC | 396.00k | -3.14m | 2.30m | 9.00 | -- | 0.6312 | -- | 5.80 | -0.0114 | -0.0114 | 0.0014 | 0.0085 | 0.0858 | -- | 0.9766 | 44,000.00 | -67.93 | -42.50 | -81.69 | -46.66 | -- | -- | -792.17 | -1,482.46 | -- | -- | 0.00 | -- | -10.41 | -- | 22.41 | -- | -- | -- |
| N4 Pharma PLC | 5.86k | -1.12m | 2.57m | 5.00 | -- | 2.05 | -- | 437.90 | -0.0042 | -0.0042 | 0.00002 | 0.0032 | 0.0041 | -- | 0.0421 | 1,172.00 | -79.19 | -57.05 | -83.28 | -61.13 | -- | -- | -19,152.56 | -309,312.80 | -- | -3,023.17 | 0.00 | -- | -- | -51.52 | -24.05 | -- | -- | -- |
| Fusion Antibodies PLC | 1.80m | -1.63m | 4.03m | 31.00 | -- | 3.78 | -- | 2.24 | -0.0214 | -0.0214 | 0.0225 | 0.0111 | 1.01 | 3.81 | 2.92 | 58,129.03 | -90.74 | -41.50 | -125.54 | -52.23 | 20.20 | 40.19 | -90.29 | -56.92 | 2.73 | -- | 0.0293 | -- | -60.84 | -12.24 | 14.25 | -- | -72.95 | -- |
| Genflow Biosciences PLC | 0.00 | -1.53m | 6.12m | 5.00 | -- | 7.13 | -- | -- | -0.0051 | -0.0051 | 0.00 | 0.0025 | 0.00 | -- | -- | 0.00 | -93.85 | -- | -118.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.97 | -- | -- | -- |
| ImmuPharma PLC | -69.96k | -2.46m | 6.54m | 5.00 | -- | 2.43 | -- | -- | -0.0065 | -0.0065 | -0.0002 | 0.0065 | -0.019 | -- | -- | -13,992.00 | -66.99 | -86.13 | -111.20 | -106.39 | -- | -- | -- | -8,634.98 | -- | -7.27 | 0.00 | -- | -- | -- | 23.26 | -- | -- | -- |
| LungLife AI Inc | 23.04k | -3.55m | 7.32m | 15.00 | -- | 0.3556 | -- | 317.62 | -0.1334 | -0.1334 | 0.0009 | 0.2473 | 0.0027 | -- | 2.90 | 1,536.09 | -42.18 | -- | -47.78 | -- | 100.00 | -- | -15,403.45 | -- | -- | -- | 0.0259 | -- | 91.67 | -- | 28.83 | -- | -- | -- |
| Cizzle Biotechnology Holdings PLC | 0.00 | -2.70m | 7.53m | 67.00 | -- | 9.49 | -- | -- | -0.0073 | -0.0073 | 0.00 | 0.002 | 0.00 | -- | -- | -- | -146.70 | -144.15 | -157.81 | -167.75 | -- | -- | -- | -- | -- | -0.45 | 0.00 | -- | -- | -- | -88.27 | -- | -- | -- |
| Synairgen plc | 0.00 | -6.92m | 9.38m | 36.00 | -- | 0.9751 | -- | -- | -0.0344 | -0.0344 | 0.00 | 0.0475 | 0.00 | -- | -- | 0.00 | -47.18 | -54.01 | -54.24 | -60.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 52.35 | -- | -26.64 | -- |
| IXICO PLC | 6.00m | -1.87m | 11.12m | 89.00 | -- | 0.578 | -- | 1.85 | -0.0386 | -0.0386 | 0.1241 | 0.2076 | 0.4725 | -- | 3.54 | 67,415.73 | -14.69 | 4.35 | -16.58 | 5.33 | 46.90 | 62.09 | -31.10 | 6.61 | -- | -- | 0.0312 | 0.00 | -22.89 | 4.32 | -214.15 | -- | 92.12 | -- |
| OptiBiotix Health PLC | 569.00k | -2.98m | 12.00m | 5.00 | -- | 1.63 | -- | 21.09 | -0.0317 | -0.0317 | 0.0061 | 0.0752 | 0.0634 | 1.35 | 1.07 | 113,800.00 | -33.25 | 16.82 | -34.85 | 17.52 | 47.98 | 53.03 | -524.43 | 183.49 | 5.36 | -2.03 | 0.00 | 100.14 | 40.92 | 4.60 | -178.82 | -- | -- | -- |
| Incanthera PLC | 0.00 | -1.55m | 16.37m | 7.00 | -- | -- | -- | -- | -0.0189 | -0.0189 | 0.00 | -0.0061 | 0.00 | -- | -- | 0.00 | -852.34 | -115.31 | -- | -153.87 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -12.76 | -- | -- | -- |
| Hemogenyx Pharmaceuticals PLC | 0.00 | -5.18m | 21.38m | 17.00 | -- | 6.68 | -- | -- | -0.0042 | -0.0042 | 0.00 | 0.0023 | 0.00 | -- | -- | 0.00 | -77.79 | -82.19 | -85.95 | -95.97 | -- | -- | -- | -- | -- | -19.94 | 0.4794 | -- | -- | -- | -68.14 | -- | 36.68 | -- |
| Shield Therapeutics PLC | 20.88m | -36.17m | 23.07m | 73.00 | -- | 42.64 | -- | 1.10 | -0.0477 | -0.0477 | 0.0274 | 0.0007 | 0.4723 | 4.06 | 1.69 | 286,068.50 | -81.80 | -56.68 | -136.41 | -67.44 | 34.65 | 52.20 | -173.18 | -365.89 | 0.8968 | -15.29 | 0.9736 | -- | 137.95 | 1.95 | 33.13 | -- | -2.50 | -- |
Data as of Nov 22 2024. Currency figures normalised to IXICO PLC's reporting currency: UK Pound GBX
54.60%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Octopus Investments Ltd.as of 28 Oct 2024 | 16.85m | 18.18% |
| BGF Investment Management Ltd.as of 28 Oct 2024 | 12.89m | 13.91% |
| Canaccord Genuity Asset Management Ltd.as of 28 Oct 2024 | 7.47m | 8.06% |
| Canaccord Genuity Wealth Ltd.as of 30 Mar 2021 | 4.68m | 5.05% |
| Unicorn Asset Management Ltd.as of 31 Oct 2024 | 3.59m | 3.87% |
| Hargreaves Lansdown Asset Management Ltd.as of 01 Aug 2024 | 2.17m | 2.34% |
| City Asset Management Plcas of 29 Jan 2024 | 1.43m | 1.54% |
| ICBC Standard Bank Plcas of 01 Aug 2024 | 810.00k | 0.87% |
| Pilling & Co. Stockbrokers Ltd.as of 01 Aug 2024 | 502.00k | 0.54% |
| HSBC Global Asset Management (UK) Ltd.as of 01 Aug 2024 | 207.00k | 0.22% |
More ▼
Data from 10 Sep 2024 - 05 Nov 2024Source: FactSet Research Systems Inc.
